Enovis (NYSE:ENOV) Updates FY 2026 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 3.520-3.730 for the period, compared to the consensus earnings per share estimate of 3.630. The company issued revenue guidance of $2.3 billion-$2.4 billion, compared to the consensus revenue estimate of $2.3 billion.

Enovis Stock Performance

Shares of ENOV stock opened at $24.87 on Thursday. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -1.20 and a beta of 1.41. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The company has a 50-day simple moving average of $23.78 and a 200 day simple moving average of $25.83. Enovis has a 52 week low of $21.00 and a 52 week high of $37.85.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. The business had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, sell-side analysts predict that Enovis will post 3.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on ENOV shares. Evercore reaffirmed an “outperform” rating on shares of Enovis in a report on Monday, January 12th. Wall Street Zen downgraded shares of Enovis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Needham & Company LLC lifted their target price on shares of Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, Wells Fargo & Company raised shares of Enovis to a “strong-buy” rating in a report on Wednesday, March 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $47.43.

Insider Transactions at Enovis

In other Enovis news, insider Oliver Engert acquired 1,000 shares of the business’s stock in a transaction on Friday, February 27th. The stock was purchased at an average price of $25.50 per share, with a total value of $25,500.00. Following the acquisition, the insider directly owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. This trade represents a 2.35% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have bought 5,000 shares of company stock valued at $121,983. Insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

A number of institutional investors have recently bought and sold shares of ENOV. Rubric Capital Management LP bought a new stake in Enovis in the 3rd quarter valued at about $83,435,000. AQR Capital Management LLC boosted its holdings in Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after purchasing an additional 434,646 shares during the period. Paradigm Capital Management Inc. NY boosted its holdings in Enovis by 41.6% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 1,113,300 shares of the company’s stock valued at $34,913,000 after purchasing an additional 326,900 shares during the period. ExodusPoint Capital Management LP boosted its holdings in Enovis by 163.4% in the 4th quarter. ExodusPoint Capital Management LP now owns 508,971 shares of the company’s stock valued at $13,559,000 after purchasing an additional 315,711 shares during the period. Finally, Soleus Capital Management L.P. bought a new stake in Enovis in the 2nd quarter valued at about $9,878,000. Institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.